DUBLIN--(BUSINESS WIRE)--The "Global Lab Automation Market for In-vitro Diagnostics Market - Segmented By Equipment End User, and Region - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global lab automation market for in-vitro diagnostics market was valued at USD 949.1 million in 2017 and is expected to reach a value of USD 1,230.9 million by 2023 at a CAGR of 4.43% over the forecast period (2018-2023).
There exists a potential for the risk of harming the patient, due to the generation of inaccurate test results, as these results are known to have a 70% impact on the healthcare decisions taken. Thus, any form of inaccuracy could lead to the mismanagement of a patient's disease or condition.
Given this potential risk, as well as the impact on the overall delivery of health care, the governments have assumed a role in the regulation of IVDs through several agencies, including the Food and Drug Administration (FDA), ISO, and the Centers for Medicare & Medicaid Services (CMS).
Key Highlights
- Digital Transformation of Lab Aids the Market Growth
- Laboratories are the Largest Consumer
- UK to be the Dominant Market
Topics Covered
1. Introduction
2. Research methodology
3. Market Insights
4. Market Dynamics
5. Global Lab Automation Market for In-Vitro Diagnostics Market - Segmentation
6. Competitive Intelligence
7. Investment Analysis
8. Future of Lab Automation for IVD Market
Companies Profiled
- Cognex Corporation
- Roche Holding AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies Inc.
- Abbott Laboratories Inc.
- PerkinElmer Inc.
- Tecan Group Ltd.
- Becton Dickinson and Co.
- Siemens Healthcare GmbH
- Bee Robotics Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/7sfskf/lab_automation?w=4